×

Biotech and Pharmaceuticals Medicine

  • April 5- Japan's Takeda Pharmaceutical said on Wednesday it had completed enrolment for a 20,000- subject dengue vaccine trial, the largest clinical study in its history, signaling the global ambitions of its vaccine business. Japan's largest drugmaker has taken a conscious decision to become more international under its French CEO Christophe Weber, who...

  • CHICAGO, April 4- About one in 10 pregnant women with confirmed Zika infections had a fetus or baby with birth defects, offering the clearest picture yet of the risk of Zika infection during pregnancy, U.S. researchers said on Tuesday. The report from the Centers for Disease Control and Prevention is the first to analyze a group of U.S. women with clear, confirmed...

  • Vice President Mike Pence.

    White House officials made a new offer to conservative House Republicans late Monday on the GOP's failed health care bill, hoping to resuscitate a measure that crashed spectacularly less than two weeks ago.

  • LONDON, April 3- An experimental drug spun off by AstraZeneca last year to an unlisted U.S. biotech firm could cut menopausal hot flashes by nearly three-quarters, according to results from a small mid-stage clinical trial. The British drugmaker licensed rights to the medicine, which is given as a pill, to Millendo Therapeutics as part of its strategy to divest...

  • Senator Rand Paul (L), Republican of Kentucky, speaks to the media after arriving back at the White House in Washington, April 2, 2017, after playing golf with President Donald Trump.

    President Donald Trump golfed with a vocal Republican critic of his healthcare push on Sunday, as he insisted efforts to repeal and replace President Barack Obama's signature healthcare law were not dead.

  • April 3- Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year. The industry's pipeline of cancer drugs expanded by 63 percent between 2005 and 2015, according to the QuintilesIMS Institute, and a good number are reaching the market.

  • March 31- A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, causing the stock to tumble 24 percent before trading was halted. District Judge Leonard Stark opens the door for generic versions of the drug by companies including Mylan Inc and Roxane Laboratories Inc..

  • March 31- A federal judge in Delaware on Friday struck down key patents held by Acorda Therapeutics Inc related to its multiple sclerosis drug Ampyra, and the stock fell 24 percent before being halted. District Judge Leonard Stark opens the door for generic versions of the drug by makers including Mylan Inc and Roxane Laboratories Inc.. Sales of Ampyra...

  • UK- based Oxford BioMedica's shares get a lift. ZURICH, March 30- A new leukaemia treatment from Novartis for children and young adults will get priority review from the U.S. Food and Drug Administration, putting the Swiss drugmaker ahead of rivals working on similar cancer therapies. The FDA's announcement late Wednesday means the regulator plans to take...

  • *UK- based Oxford BioMedica's shares get a lift. ZURICH, March 30- A new leukemia treatment from Novartis for children and young adults will get priority review from the U.S. Food and Drug Administration, putting the Swiss drugmaker ahead of rivals working on similar cancer therapies. The FDA's announcement late Wednesday means the regulator plans to take action...

  • ZURICH, March 29- Roche's multiple sclerosis drug Ocrevus won U.S. approval, putting the potential blockbuster back on track after a brief delay and giving a lift to patients with a form of the disease that until now had no approved treatment. The drug, also known as ocrelizumab and administered via infusion, becomes the first U.S. Food and Drug Administration-...

  • March 28- The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies. Wall Street analysts forecast annual sales exceeding $4 billion by 2022 for the biotech drug known chemically as...

  • March 28- The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies. Wall Street analysts forecast annual sales exceeding $4 billion by 2022 for the biotech drug known...

  • CHICAGO, March 27- Georgia has confirmed its first-ever case of bird flu in commercial poultry, its agriculture department said on Monday, widening an outbreak of the disease into the United States' biggest chicken meat-producing state. The discovery came after officials in Alabama, Kentucky and Tennessee confirmed cases of highly pathogenic, or lethal, and...

  • March 27- The U.S. Food and Drug Administration on Monday approved Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer. The U.S. biopharmaceutical company's shares were up 7.78 percent at $168.9 in extended trading. Tesaro expects to launch niraparib in the United States in late April.

  • March 27- The U.S. Food and Drug Administration on Monday approved Tesaro Inc's drug, niraparib, for the treatment of recurrent ovarian cancer.

  • By Divya Grover and Natalie Grover. March 27- Foamix Pharmaceuticals Ltd said on Monday its experimental acne treatment failed to meet one of two main goals in a late-stage study, pushing its shares down about 42 percent. However, the drug, FMX101, succeeded in a separate late-stage study, the Israel- based drug developer said.

  • LONDON, March 27- International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment. If the latest patent challenge is successful, it could make cheaper generic versions of sofosbuvir available in...

  • March 27- Foamix Pharmaceuticals Ltd said its experimental acne drug failed to meet one of two main goals in a late-stage study, sending its shares down about 30 percent in premarket trading. However, the drug, FMX101, induced a statistically significant benefit in a separate late-stage study, the Israel- based drug developer said. Acne is the most common skin...

  • *Mutation very common China, opening big sales opportunity. LONDON, March 27- AstraZeneca has won approval for its lung cancer pill Tagrisso in China, a key market for the potential blockbuster medicine. Tagrisso is designed to help cancer patients with certain genetic mutations that are very common in China and the regulatory green light boosts the British...